ENZN Enzon Pharmaceuticals Inc

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.65    OTCQX
As of 06/23/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  02/15/1984
Outstanding shares:  74,214,603
Average volume:  5,155
Market cap:   $48,239,492
Current dividend yield:  64.80%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    293904108
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   -9.17
PB ratio:   2.69
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy